In this study, the AFP, CA199, CEA and HIF-1 indexes of the two groups decreased after treatment, and the AFP, CA199, CEA and HIF-1 indexes of group A were significantly lower than those of group B, suggesting that apatinib combined with camrelizumab Antibiotics can further reduce the level of serum tumor markers in HCC patients. Here, AFP is linked to hepatocellular carcinoma.